A detailed history of Walleye Capital LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 104,960 shares of XENE stock, worth $4.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
104,960
Holding current value
$4.02 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.12 - $43.96 $3.79 Million - $4.61 Million
104,960 New
104,960 $4.13 Million
Q4 2023

Feb 14, 2024

SELL
$28.7 - $46.46 $3.47 Million - $5.62 Million
-120,974 Reduced 95.99%
5,054 $232,000
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $1.24 Million - $1.44 Million
36,324 Added 40.49%
126,028 $4.31 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $544,479 - $680,443
-15,628 Reduced 14.84%
89,704 $3.45 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $629,549 - $759,185
18,815 Added 21.75%
105,332 $3.77 Million
Q4 2022

Feb 14, 2023

SELL
$33.06 - $39.43 $48,069 - $57,331
-1,454 Reduced 1.65%
86,517 $3.41 Million
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $2.28 Million - $2.94 Million
-73,956 Reduced 45.67%
87,971 $3.18 Million
Q2 2022

Aug 08, 2022

BUY
$25.44 - $35.16 $193,827 - $267,884
7,619 Added 4.94%
161,927 $4.93 Million
Q1 2022

May 16, 2022

BUY
$25.09 - $33.13 $2.07 Million - $2.73 Million
82,324 Added 114.36%
154,308 $4.72 Million
Q4 2021

Mar 03, 2022

BUY
$15.6 - $35.4 $1.12 Million - $2.55 Million
71,984 New
71,984 $2.25 Million
Q1 2019

May 15, 2019

SELL
$6.39 - $10.42 $48,864 - $79,681
-7,647 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$9.0 - $14.9 $68,823 - $113,940
7,647 New
7,647 $101,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.